Legends leave Legacys~
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bear raid, possibly.. Healthy pull back, sure.. Most of the smart money here knows whats about to come next week$ its pretty evident from the EOD trading yesterday and todays HUGE shake~
$MoneyMonday$
RFMK puttin on its getty up sticks! $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Smart money knows the play here! Cant wait for this coiled spring to unleash!
Haha! Nice~ $RFMK$
Was it due to the demise of the station?
A slingshot always has to be pulled back before it fires! $RFMK$
Great opportunity to scoop, i mean SHOVEL in some more shares
Today an Inverted Umbrella was formed. The long upper shadow shows the evidence for selling pressure, but the position of high price indicates that plenty of buyers still are around.
Today a Black Candlestick was formed. This represents normal selling pressure.
NABIS SCIENCE (NASDAQ:CBIS) Uptrend
Smart Scan Chart Analysis confirms that a short term counter trend move is underway. When this action is over look for the longer term positive trend to resume. Uptrend with money management stops.
Based on a pre-defined weighted trend formula for chart analysis, CBIS scored +85 on a scale from -100 (strong downtrend) to +100 (strong uptrend):
+10 Last Hour Close Above 5 Hour Moving Average
-15 New 3 Day Low on Wednesday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, Week Ending January 21st
+30 New 3 Month High in January
+85 Total Score
Ive personaly never been involved with a "buy back" if thats what is about to begin? Can anybody fill me in on the risks involved? Is there a certain date one would have to be invested by? The DD ive done shows this could be very positive for a shareholder!
Nice work!
Nice work! Great DD!!
ABIS SCIENCE (NASDAQ:CBIS) Uptrend
Smart Scan Chart Analysis is showing some near term weakness. However, this market remains in the confines of a longer term Uptrend with tight money management stops.
Based on a pre-defined weighted trend formula for chart analysis, CBIS scored +75 on a scale from -100 (strong downtrend) to +100 (strong uptrend):
-10 Last Hour Close Below 5 hour Moving Average
-15 New 3 Day Low on Wednesday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, Week Ending January 21st
+30 New 3 Month High in January
+75 Total Score
Lets go $RIGH!$
RFMK is fuming with success! Not do they only have two products almost ready for market, they also have a built in marketing company, and a proffessional managment team as well! Plus a petent and a CEO who obviously cares about his shareholders as well! 19% without any news is nothing compared to whats instore!!! $RFMK$
I beleive the longs will prosper well in this play, but i gotta say, that was a very well written post!
Hmmm...
CANNABIS SCIENCE (NASDAQ:CBIS) Uptrend
Smart Scan Chart Analysis confirms that a short term counter trend move is underway. When this action is over look for the longer term positive trend to resume. Uptrend with money management stops.
Based on a pre-defined weighted trend formula for chart analysis, CBIS scored +85 on a scale from -100 (strong downtrend) to +100 (strong uptrend):
+10 Last Hour Close Above 5 Hour Moving Average
-15 New 3 Day Low on Wednesday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, Week Ending January 21st
+30 New 3 Month High in January
+85 Total Score
Closing green! Imo $RFMK$
Welcome to PR Canna Zine.
PR. Public Relations
PR. Press Release
PR. Positive Response
FAQ - Start HereLinksUK Cultivator Cannabis ForumsContact Us
Home Green/Eco/Environment Green news Successful Cannabis Cancer Treatment Seeking FDA Approval
Successful Cannabis Cancer Treatment Seeking FDA Approval
2
digg
A 'patient administered' cannabis based treatment which has shown remarkable successes when used against different cancers, will now seek FDA approval in the United States.
Cannabis Science inc (CBIS) has provided spectacularly successful evidence on a number of different patients who self-medicated with their cannabis extract.
Doctors agree time is of the essence when dealing with cancer and for cannabis treatments the signs are good as the treatments show dramatic signs of improvement in days and weeks, instead of months.
One patient who suffered basal cell carcinoma applied topical applications of CBIS cannabis extracts to a clinically
diagnosed cancer and within 10 days the lesion had gone entirely.
Please sign the government petition which will give patients unmolestered access to the cannabis treatment which could save their lives. http://epetitions.direct.gov.uk/petitions/29
In another case the patient had such an aggressive form of squamous cell carcinoma on his head, it caused one cancer doctor to 'relieve himself' from the case and a second cancer doctor to almost do the same, so hopeless was the prognosis.
Yet after just a couple of weeks of CBIS cannabis treatment the patient has made a remarkable turn-around.
TRULY remarkable. You can CLICK HERE to see the results for yourself.
In the UK there are tens of thousands of skin cancer cases every single year, some of which become terminal if left untreated for too long.
Yet here is a low toxicity natural plant extract with a remarkably safe side effect profile, being sold on the High Street in the US for just a few dollars, which could dramatically improve the prognosis for those patients, without them having to endure weeks and weeks of highly toxic chemotherapy, radiotherapy, and the debilitating symptoms associated with the treatments.
Check out Cannabis Science inc (CBIS) for more information and then perhaps you could write and tell your MP about it?
Having the right treatment available should not be about what colour your passport is.
Cannabis is making great strides in the fight against cancer as well as a host of other conditions, but due to a lack of courage in British politics, British citizens continue to die. Or they face arrest and incarceration simply for wishing to try a cannabis based treatment.
The 'public health' risk of cannabis has been rationalised many times. The risks to a patient who uses cannabis are absolutely minimal, and according to Peter Reynolds from Cannabis Law Reform (CLEAR-UK ), "There is now no doubt that cannabis extracts can have a dramatic effect on skin cancer. There's a huge leap between this and some of the wilder claims about cannabis and cancer but it is vital that proper research gets underway."
"What is the Department of Health doing about it?"
What indeed? Excuses are no longer going to cut the mustard.
Legalise Cannabis now. Or at the very least deregulate it so people may procure their own supply.
It can mean the difference between life and death for these patients.
Cannazine Cannabis News
Comments
Add New Search RSS
Write comment
Name:
Website:
Title:
Please input the anti-spam code that you can read in the image.
Powered by !JoomlaComment 3.12
< Prev Next >
[ Back ]
Penny Stock on the Move: Rapid Fire Marketing Inc. (RFMK)
Thursday, January 26th, 2012 | Filed under Internet,Stocks | Posted by Adam Garcia
Shares of Rapid Fire Marketing Inc. (PINK: RFMK), a provider of full service marketing, consulting and management services for medical cannabis in the U.S., saw a huge rally in Wednesday’s trading session. The penny stock of Rapid Fire Marketing ended the day 31.58% higher at $0.0050, with volume up from daily average of 7.80 million to 37.03 million.
Rapid Fire Marketing shares surged in Wednesday’s trading session after the company announced that Medical Cannabis Management (MCM) received the first shipment of new THC e-Cig. The new THC e-Cig, which is called CannaCig, will be available for purchase at physicians and many medical cannabis dispensaries over the coming days through marketing arrangements made with a number of key individuals in the medical cannabis dispensary business.
Mike Amezquita, CEO of MCM, said that the company has been working very hard over the last couple of months to get the product into the marketplace as quickly as possible.
This newsletter has been helping traders make a killing on RFMK. Click here for a 25% discount offer.
See today’s top stock picks and market analysis
Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
Want more? Check out the message board buzz for RFMK
See what newsletters are recommending this stock pick
Get breaking news alerts on these stocks: http://thestockmarketwatch.com/
Cant wait for a tabloid or TMZ to come out with pics of a celeb using the CannaCig! Just a thought~ $RFMK$
Ok, but are any of those publicly traded on a global level??
Sent emails with links to several sydicated talk radio shows! It would be great if we could build momentum before the next PR!~
Does anyone know who will be supplying the "cartridges" for the CannaCig? Or any details on them?
I saw the article and copy n pasted it quick, sorry might not have highlighted it all the way~
Agreed~
Penny Stock in Focus: Cannabis Science Inc. (CBIS) to begin IND application with FDA
Thursday, January 26th, 2012 | Filed under Breaking News,Internet | Posted by Terrel Sugar
Shares of Cannabis Science Inc. (OTC: CBIS), a medical marijuana company, climbed in Wednesday’s trading session. The penny stock of Cannabis Science ended the day 3.57% higher at $0.0435, with volume up from daily average of 16.03 million to 32.26 million.
Cannabis Science on Wednesday announced that the current progress and success with its numerous self-medicated cancer patients has led it to the immediate start of the Investigational New Drug (IND) application process that will target cancer treatment.
Cannabis Science said that it is currently tracking a number of cancer patients, who are self-medicating with cannabis extracts. The company said that there is evidence of success with a number of these patients, which lends support to an IND application to the FDA.
The company believes that it is an excellent position to start the FDA process for prescription cancer medications.
PowerHour should be a fun ride today~
Rapid Fire Marketing Inc (PINK:RFMK) Keeps Climbing Up at Full Speed
By Nelly Shishkova
Jan 26, 2012
Rapid Fire Marketing Inc (PINK:RFMK, RFMK message board) has been moving up progressively over the past days. Yesterday, the stock hit a phenomenal gain by soaring another 31.58% and trading over 37 million shares for the day.
Apparently, the massive trade has been caused by the latest news on RFMK. It was just yesterday when the company reported that one of its subsidiaries, Medical Cannabis Management, has received their first shipment of their new THC e-Cig. While the first edition of CannaCig is going to the market, the second edition is expected to be ready in 30-60 days.
Being reported, the optimistic statements pumped up RFMK stock price at once. Now, it is interesting whether the news will hold the gain for longer.
Rapid Fire Marketing, Inc. operates through two subsidiaries, Medical Cannabis Management and Bioniccigs.com. In the beginning of this week, RFMK filed its annual results but these did not look that promising.
Until December 31, 2011 the company's cash and cash equivalents have decreased as compared to the year before, while its accumulated deficit tripled. Besides, the net loss and expenses have not been covered.
As a result, RFMK is not profitable yet and keeps waiting for better times.
Warmin up~!
A PR noting the estimated future sales would be major eye candy today!
Nice! Any article with the term "Mega Profits" in the title is good news! CBIS$$$$$$$
oOoRMFK!!oOo C'mon baby!
Hows the L2 looking??
Can someone explain what happens when the symbol changes?
Any predictions on where we close on friday?
Hmmm... Possibly refering to CBIS??
Invest In This Emerging Multibillion-Dollar Market
By Patrick Cox
January 24, 2012
The business of medical biotechnologies operates within an extraordinarily complex regulatory system.
The SEC and the IRS are only the beginning of the story...
In the United States, the Food and Drug Administration determines what can legally be sold. It even exercises control over what can be said by companies about medical therapies. Elsewhere, other regulatory authorities play similar roles.
It was not always that way, of course. Prior to the 20th century, there was virtually no regulation of medical therapies. Medical decisions were considered the domain of doctors and patients, who bore the responsibilities and risks associated with the use of any product. Even currently banned Class A drugs used for recreational purposes were available for sale without limitations.
Today, the average cost of bringing a medical product from conception to market is around $400 million, according to The Cato Institute. The time required can be as long as 10 years.
As a result, the FDA is widely considered in need of major reform, though the nature of those reforms is a matter of debate. Responding to criticisms, the FDA has implemented some programs to accelerate review procedures.
Cancer “Magic Bullet?” Small Biotech Set to Rocket?
A little-known biotech company is making medical history... but with FDA fast track review status for their cancer treatment, this small company might not stay “little-known” for long...
So you must move fast if you want to get in on the ground floor of what could be the biggest medical breakthrough in decades...
Click here to learn more now.
For example, Big Pharma is allowed to directly pay the costs of the process in some cases, which can result in a faster ruling. The FDA’s response to criticisms has often focused on the need for more money to accelerate reviews. Given budgetary pressures created by the financial and entitlement crises, this is unlikely. The FDA’s desire to expand oversight is, therefore, not likely to be accomplished, in the near term at least.
The FDA currently controls only the initial approval of a therapy. It does not prohibit the use of approved therapies for uses other than which they were approved, though many in the agency would clearly like to take over what is a far-less-regulated market than many believe. These unapproved, but legal, uses are referred to as off-label.
Currently, biotechs typically target applications with the highest probability of approval, knowing that a drug or device will be widely used for unapproved purposes as soon as it is available for sale. However, the FDA prohibits the advertising of uses other than those for which a therapy was approved.
The FDA has also become very aggressive policing the publication of unapproved medical information by companies that do not sell drugs. Recently, for example, the FDA sent Diamond Foods a letter stating, “your walnut products are drugs,” because the company had publicized well-documented research about the benefits of omega-3 fatty acids found in walnuts. Diamond was threatened with “seizure” if the company did not immediately stop educating the public to the benefits of walnuts.
The move is rife with irony, as the National Institutes of Health has lagged decades behind nutritional researchers regarding fats in general. For many years, the federal government officially endorsed the old, simplistic food-pyramid philosophy based on the notion that all fat consumption should be reduced. Researchers have shown, overwhelmingly, that most people are deficient in certain essential fats... especially omega-3s, which play an important role in reducing heart disease and other diseases.
Many consumers don’t have that understanding and could benefit from it, but the FDA frequently prevents companies from talking about the benefits of their products. This, by the way, is an example of what my dietitian wife calls regulatory “information hoarding.”
Diamond Foods, of course, quickly complied with the FDA’s ban on unapproved educational activities. However, the event highlights the tension between the agency and providers of natural products that may have health benefits.
This tension was codified in the Dietary Supplement Health and Education Act of 1994 (DSHEA). Sponsored by Sens. Tom Harkin (D- Iowa) and Orrin Hatch (R-Utah), the law specifically excludes naturally occurring substances, sold as dietary supplements, from the FDA approval process.
This was, in a sense, the birth of the modern American nutraceutical industry. Combining the words “nutrition” and “pharmaceutical,” nutraceuticals are foods or substances derived from foods, either synthesized or purified, and sold for health benefits. In Japan, the nutraceutical market emerged in the 1980s. Today, almost half of all Japanese consume nutraceutical products. The U.S., however, is catching up. Drug and health food stores have long stocked a wide range of nutraceuticals.
Increasingly, even grocery stores dedicate shelf space to natural products ranging from natural vitamin supplements to electrolyte- rich sports drinks.
Furthermore, we are also seeing nutraceuticals increasingly appear in foods to promote good health. Many foods are now being fortified with health-promoting ingredients. These include cereals with added omega-3 fatty acids, fruit juices with herbal ingredients that have biochemical properties and milk with vitamin D.
Even more esoteric products are sold in GNC and sports-oriented supplement stores. While many products may have little or no real value, it’s also clear that some have powerful biological effects.
One such product is creatine, 2-(methylguanidino) ethanoic acid. Creatine is a nitrogenous organic acid that occurs naturally in vertebrates, thus qualifying the product for nutraceutical status. It helps supply energy to all cells in the body, though most users are probably primarily interested in its effects on muscle cells...